Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/26202
Title: Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogs for patients at risk of renal failure after liver transplantation: a prospective single center cohort study
Authors: BIELEN, Rob 
ROBAEYS, Geert 
Schelfhout, Sigrid
Monbaliu, Diethard
Van der Merwe, Schalk
Pirenne, Jacques
Nevens, Frederik
Issue Date: 2018
Source: TRANSPLANT INTERNATIONAL, 31 (5), p. 503-509
Abstract: Currently, nucleos(t)ide analogs (NAs) in monotherapy are favored as prophylaxis against hepatitis B recurrence after liver transplantation. However, in patients at risk of renal failure, renal safety of NAs is of concern. We investigated the safety and efficacy of subcutaneous (SC) hepatitis B immunoglobulins (HBIG) in monotherapy. This is a single-arm prospective trial in patients transplanted >1 year. We included 43 Caucasian patients. The majority was treated with calcineurin inhibitors, and several patients had other risk factors for renal impairment as well: diabetes mellitus (n = 10/43), arterial hypertension (n = 11/43), and hyperlipidemia (=10/43). At inclusion, 42% (n = 18) had chronic kidney disease grade 3a. All patients were switched from IV HBIG with or without NAs to SC HBIG without NAs. After one year, the targeted titer was lowered to 150 IU/l in patients with low risk of recurrence. Mean follow-up time was 36 +/- 5 months. None of the patients had a relapse of HBsAg or HBV DNA. The treatment was well tolerated, safe and the renal function remained unchanged both in patients with (n = 18) or without (n = 25) renal impairment at baseline. The mean HBsAb titer could be decreased from 343 +/- 163 to 199 +/- 81 IU/l in the low-risk group (n = 17) and 218 +/- 71 IU/l in the high-risk group (n = 26). In 86% (n = 37) doses, reductions were possible, which significantly lowered the cost of treatment. SC HBIG without NAs had a 100% success rate in the long-term prevention of HBsAg and HBV DNA reappearance, without deterioration of renal function.
Notes: Bielen, R (reprint author), Ziekenhuis Oost Limburg, Dept Gastroenterol & Hepatol, Schiepse Bos 6, B-3600 Genk, Belgium. rob.bielen@uhasselt.be
Keywords: hepatitis B; immunoglobulin; liver transplantation; nephrotoxicity
Document URI: http://hdl.handle.net/1942/26202
ISSN: 0934-0874
e-ISSN: 1432-2277
DOI: 10.1111/tri.13112
ISI #: 000430188200006
Category: A1
Type: Journal Contribution
Validations: ecoom 2019
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
bielen 1.pdf
  Restricted Access
Published version212.55 kBAdobe PDFView/Open    Request a copy
peer reviewed author version.pdfPeer-reviewed author version296.42 kBAdobe PDFView/Open
Show full item record

SCOPUSTM   
Citations

3
checked on Sep 2, 2020

WEB OF SCIENCETM
Citations

3
checked on May 21, 2022

Page view(s)

74
checked on May 20, 2022

Download(s)

112
checked on May 20, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.